Memorial Sloan Kettering Cancer Center

https://www.mskcc.org/healthcare-professionals

Refer a Patient to MSKCC: mskcc.org/refer

 

Lung
16:46

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NRG-LU002 Trial - Maintenance Systemic Therapy +/- Local Consolidative Therapy in Limited mNSCLC"

FEATURING Puneeth Iyengar
  • 80 views
  • June 13, 2024
14:26

Memorial Sloan Kettering Cancer Center

Radiation for Unresectable NSCLC: Where Are We Now and Where Are We Going

FEATURING Daniel Gomez
  • 148 views
  • December 13, 2023
  • 3
26:21

Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metastatic Setting

FEATURING Michael Hwang
  • 982 views
  • December 13, 2023
  • 11
14:52

Memorial Sloan Kettering Cancer Center

Advances in Resectable NSCLC

FEATURING Katherine Gray
  • 151 views
  • December 13, 2023
  • 1
09:38

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "CDC7 Inhibition Constrains Lineage Plasticity and Prevents Resistance and Neuroendocrine Transformation in the Lung and Prostate"

FEATURING Alvaro Quintanal-Villalonga
  • 275 views
  • November 24, 2023
06:04

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "Durable Efficacy of Zenocutuzumab, a HER2 x HER3 Bispecific Antibody, in Advanced NRG1+ NSCLC"

FEATURING Alison Schram
  • 90 views
  • November 24, 2023
14:02

Insights from 2023 WCLC

WCLC 2023 Insights: "MSI and MMR-D Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High TMB, and MLH1 Inactivation"

FEATURING Soo-Ryum Yang
  • 119 views
  • November 17, 2023
  • 3
10:18

i3 Health

Additional Advances in Squamous NSCLC Research and Clinical Trials

FEATURING Mark Kris
  • 110 views
  • January 31, 2023
  • 2
08:03

i3 Health

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion-Mutant NSCLC

FEATURING Helena Yu, Maria Arcila
  • 101 views
  • August 3, 2021
  • 1
10:16

Memorial Sloan Kettering Cancer Center

2021 ASCO Updates on KEYLYNK-013 Study for Newly Diagnosed LS-SCLC: Pembro+CCRT Followed by Pembro +/- Olaparib vs. CCRT

FEATURING Andreas Rimner
  • 252 views
  • June 16, 2021
05:59

Memorial Sloan Kettering Cancer Center

2021 ASCO Updates on METex14 Skipping mNSCLC: ctDNA Dynamics & Resistance Mechanisms Detected in Liquid Biopsy From Patients Treated With Tepotinib

FEATURING Paul Paik
  • 171 views
  • June 16, 2021
  • 2
20:40

Memorial Sloan Kettering Cancer Center

Can TTFields with Chemotherapy Improve Clinical Outcome in the First-Line Setting of the Malignant Pleural Mesothelioma? Outcomes of the STELLAR Phase 2 Trial

FEATURING Charles B. Simone II
  • 114 views
  • May 28, 2020
17:52

Memorial Sloan Kettering Cancer Center

Malignant Pleural Mesothelioma: What Do Clinical Trials Suggest on Angiokinase Inhibitors, Immunotherapy Options, and Combination Strategies?

FEATURING Marjorie Zauderer
  • 266 views
  • May 25, 2020
  • 1
16:53

Memorial Sloan Kettering Cancer Center

Should We Combine EGFR TKIs With Upfront Radiation Therapy in EGFR+ NSCLC Brain Metastases?

FEATURING Kathryn Beal
  • 205 views
  • May 28, 2020
  • 3
21:24

GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

FEATURING Helena Yu
  • 4,785 views
  • August 2, 2019
  • 29
19:58

Beacon Medical Interchange

Current Practice & Challenges in Execution of Genomic Testing in Advanced NSCLC

FEATURING Jack West, Gregory Riely
  • 319 views
  • September 24, 2019
  • 1
28:12

Beacon Medical Interchange

Should Local Ablation Therapy in Oligometastatic or Oligoprogressing Advanced NSCLC Be Incorporated Into Routine Practice?

FEATURING Jack West, Gregory Riely
  • 25 views
  • September 24, 2019
23:26

GRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

FEATURING Helena Yu
  • 179 views
  • July 22, 2019
  • 1
09:30

GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

FEATURING Helena Yu
  • 33 views
  • July 22, 2019
  • 1
07:39

Nebraska Oncology Society

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III Trials? How Effective Is Lurbinectedin in Stage IV Disease Progressed After 1L Therapy?

FEATURING Gregory Riely
  • 93 views
  • October 13, 2020
16:08

Nebraska Oncology Society

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemotherapy and IO Combination in Disease Without an Oncogenic Driver?

FEATURING Gregory Riely
  • 122 views
  • October 13, 2020